The trademark application DULAVIGO was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on February 26, 2018, and it was registered by office on June 5, 2018 without any oppositions.
The application was filed in English (Spanish was selected as the second language).
Change of name and address of the trademark registration was recorded on January 24, 2022. Change of name and professional address of the trademark registration was recorded on February 3, 2022.